Mammoth Biosciences Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2017

Location

Brisbane CA US

Primary Industry

Biotechnology

About

Based in California, US, and founded in 2017 by Ashley Tehranchi, Janice Chen, Jennifer Doudna, Lucas Harrington, and Trevor Martin, Mammoth Biosciences Inc. (Mammoth) operates as a biotechnology company that develops the CRISPR-based detection platform that is capable of sensing any biomarker or disease with DNA/RNA. As of September 2021, Mammoth Biosciences has over 100 employees. In September 2021, the company received USD 150 million from Redmile Group, with participation from Foresite Capital, Senator Investment Group, Sixth Street, Greenspring Associates, Mayfield, Decheng Capital, and others. The company offers CRISPR-based therapeutics products and diagnostics to cure and detect a wide range of diseases intended to help medical professionals to improve the diagnostics process of disease detection. Mammoth Biosciences Inc. will use the September 2021 funding to expand its toolkit of next-generation CRISPR systems with a focus on building permanent genetic cures through in vivo gene-editing therapeutics and democratizing disease detection with on-demand diagnostics.

Current Investors

Kairos, Mayfield Fund, 8VC

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Diagnostic, Medical & Imaging Laboratories

Website

www.mammoth.bio

Company Stage

Series D

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.